Genzyme Corp.'s Series N warrants on Tuesday began tradingseparately from Neozyme II Corp., a research and developmentcompany
A Series N warrant, share of Neozyme II and a callable warrantwere part of a 2.1 million-unit offering (NASDAQ:NIIUF) lastMarch that raised close to $70 million to fund development of apotential cystic fibrosis treatment using gene replacement andgene therapy.
The Series N warrants, which are now listed on the NASDAQunder the symbol GENZZ, are an option to purchase a share ofGenzyme common stock at an exercise price of $38.25 through1996. Trading in the warrants closed Tuesday at $28. Genzyme(GENZ) closed at $52.38 a share, down 38 cents; the units were$22.50.
(c) 1997 American Health Consultants. All rights reserved.